Jamie Aleba, PA
Medical · Great Falls, MTNPI 1184929572
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 39 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 13 manufacturers reported payments, led by AbbVie at 36.5% of the total.
Across 39 payments — averaging $17.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$251
- Bristol Myers Squibb$86
- GSK$80
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$48
- Takeda Pharmaceuticals U.S.A., Inc.$41
- Aimmune Therapeutics, Inc.$38
- plus $144 from 7 others
What the payments were for
- Food & beverage$687100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 17 | $251 |
| Bristol Myers Squibb | 5 | $86 |
| GSK | 3 | $80 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $48 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $41 |
| Aimmune Therapeutics, Inc. | 2 | $38 |
| Johnson & Johnson | 1 | $29 |
| Madrigal Pharmaceuticals | 1 | $26 |
| Boston Scientific | 1 | $22 |
| Orphalan Inc | 1 | $19 |
| Phathom Pharmaceuticals, Inc. | 1 | $16 |
| Daiichi Sankyo Inc. | 1 | $16 |
| Sanofi | 1 | $15 |
How this compares
$687 in reported general payments places this provider in the 70th percentile of 134 medical providers in Montana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 32 | $302,957 |
| Cyltezo(Cf) PenAdalimumab-Adbm | 11 | $168,411 |
| LinzessLinaclotide | 169 | $98,990 |
| XeljanzTofacitinib Citrate | 13 | $73,984 |
| IbsrelaTenapanor Hcl | 31 | $56,578 |
| XifaxanRifaximin | 16 | $49,745 |
| RelistorMethylnaltrexone Bromide | 19 | $42,606 |
| CreonLipase/Protease/Amylase | 18 | $33,674 |
| Mesalamine | 54 | $31,497 |
| Budesonide DrBudesonide | 61 | $28,767 |
| ZenpepLipase/Protease/Amylase | 20 | $26,479 |
| VoqueznaVonoprazan Fumarate | 15 | $9,306 |
| Budesonide EcBudesonide | 28 | $9,065 |
| Dexlansoprazole DrDexlansoprazole | 44 | $7,551 |
| Mesalamine ErMesalamine | 24 | $6,897 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLinzess, Creon | $251 | $132,664187 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Relistor | $48 | $92,35135 claims |
| Aimmune Therapeutics, Inc.Zenpep | $38 | $26,47920 claims |
| Phathom Pharmaceuticals, Inc.Voquezna | $16 | $9,30615 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Motegrity | $41 | $6,47313 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 134 medical providers in Montana.
Other medical in Great Falls
- David BrostGreat Falls$7K
- Nash HallfrischGreat Falls$4K
- Timothy StreetGreat Falls$3K
- Emily ComstockGreat Falls$2K
- Chesney MartinGreat Falls$2K
- Jamie BarnesGreat Falls$1K
- Ashley WachGreat Falls$1K
- Erika BryanGreat Falls$501
- Lorianne StulcGreat Falls$483
- Joseph JoslynGreat Falls$360
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.